#USA #New York #Baird Medical #Medical Device #Mark Saxton

Baird Medical Appoints Mark Saxton as U.S. CEO

In a significant move for its operations, Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) has appointed Mark Saxton as the new Chief Executive Officer of its U.S. subsidiary. This announcement comes from the company known for its pioneering efforts in minimally invasive microwave ablation technology.

Mark Saxton brings over 25 years of well-rounded experience in the medical device sector, emphasizing his robust background in commercial leadership. His experience includes a decade in advancing intravascular RF ablation technologies. In his new role, Saxton will oversee Baird Medical’s U.S. operations, focusing on sales, marketing, and market development, which are crucial as the company intensifies its efforts to penetrate the U.S. healthcare market effectively.

A New Chapter for Baird Medical

The appointment of Saxton comes at a time when the company is looking to scale its operations and enhance its presence in the competitive medical device market. Haimei Wu, Chairwoman of Baird Medical, expressed enthusiasm about Saxton’s addition to the team. She noted his proven track record in driving novel technologies to market leadership levels and his deep expertise in thermal ablation, which she believes aligns perfectly with Baird Medical’s growth objectives.

Saxton himself expressed his excitement about joining the company, highlighting the significant advantages of Baird's Microwave Ablation platform in providing minimally invasive care. His commitment extends to advancing the U.S. commercial strategy while striving to enhance patient access and building value for shareholders.

Track Record of Success

Saxton's professional history is adorned with key accomplishments in the medtech arena. Notably, during his tenure at VNUS Medical Technologies, he spearheaded the U.S. commercialization of first-to-market intravascular RF ablation devices, resulting in an impressive revenue doubling from $49 million to over $100 million in just two years. This success played a crucial role in the company's eventual acquisition by Covidien for $512 million. Additionally, his leadership at NeuroPace was instrumental in facilitating its successful $117 million initial public offering (IPO). Furthermore, at Ceterix Orthopaedics, he successfully repositioned the company for a $105 million acquisition by Smith + Nephew.

About Baird Medical

Baird Medical focuses on advanced medical devices aiming to redefine patient outcomes through precision technology and innovative diagnostic solutions. The enterprise is deeply committed to developing surgical robotic systems and minimally invasive surgical instruments while collaborating strategically with leading academic institutions.

Notably, Baird Medical’s offerings have found their applications in over 30 renowned hospitals and clinics across the United States, including prestigious institutions like Mayo Clinic, Columbia University Medical Center, and UCSF Medical Center. Besides its solid foothold in the U.S., the company also leads the market in China for thyroid microwave ablation devices and consumables, while extending its presence in over 20 countries worldwide.

Looking Ahead

As Baird Medical transitions with its new leadership, the focus is squarely on identifying growth opportunities and meeting the rising demands of the healthcare sector in the U.S. With Saxton at the helm, the company appears poised for a promising future as it aims to deliver cutting-edge solutions and drive market expansion in minimally invasive medical technologies.

In conclusion, Baird Medical's recent steps amplify its potential in the U.S. market, positioning the company towards excelling in providing innovative, minimally invasive medical solutions under the guidance of an experienced leader like Mark Saxton.